schizophrenia

NEW HAVEN, Conn., USA — April 1, 2026 BioXcel Therapeutics, Inc. announced that the U.S. Food and Drug Administration...

New York, USA | March 27, 2026 LB Pharmaceuticals announced new findings from its Phase 2 NOVA-1 clinical trial,...

WASHINGTON, Feb. 20, 2026 — Vanda Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™...

MOUNTAIN VIEW, Calif., Feb. 13, 2026 — Alto Neuroscience announced completion of patient enrollment in its Phase 2 proof-of-concept...

December 18, 2025 | North Chicago, Illinois — Rosalind Franklin University of Medicine and Science has secured $1.73 million...

NEW YORK, November 6, 2025 — LB Pharmaceuticals Inc. (NASDAQ: LBRX), a clinical-stage biopharmaceutical company focused on developing therapies...